Cardiovascular Metabolomics

McGarrah, Robert W.; Crown, Scott B.; Zhang, Guofang; Shah, Svati H.; Newgard, Christopher B.

doi:10.1161/circresaha.117.311002

Cited by 329 publications

(239 citation statements)

References 171 publications

(185 reference statements)

Supporting

Mentioning

235

Contrasting

Unclassified

Order By: Relevance

“…(21,22) More importantly, cardiac metabolism is altered in the presence of heart failure due to decreased mitochondrial function as a result of the accumulation of medium and long chain acyl-carnitine, increased ketone metabolism and the accumulation of lactate and branch chain amino acids. (23) Patients with diabetes, therefore, are at increased risk for the development of heart failure and the prevention of heart failure is becoming a major emerging research and treatment goal such as the discovery of the sodium-glucose co-transporter 2 (SGLT2) inhibitors for the treatment of diabetes and coexistent heart failure. (24) In addition to the admission value, a graded relationship has been found between increasing blood glucose levels and MACE.…”

Section: Discussionmentioning

confidence: 99%

Admission blood glucose as a prognostic indicator in patients with acute myocardial infarction

Russel¹,

Ranjith²,

Sartorius³

2019

SAHJ

View full text Add to dashboard Cite

Objective: To investigate the utility of admission blood glucose for predicting major adverse cardiac events (MACE) during hospitalisation and 6 months' postdischarge in acute myocardial infarction (AMI) patients. Methods and results: This study recruited 2878 AMI patients admitted to the Coronary Care Unit at R. K. Khan Hospital, Durban, South Africa, from 2002 -2014. Demographic and clinical data stored in an electronic database were obtained from all patients. Admission blood glucose levels were sub-divided into 3 groups; low (<7.8), medium (7.8-10.9) and high (≥11) mmol/l. The mean age of the study population was 57.18 ± 7 years of whom 65% were males. Self-reported diabetes was found in 59%, while 377 patients were diagnosed with diabetes based on HbA1c levels ≥6.5%, increasing the overall prevalence to 72% (n=2070). More patients were in the low admission blood glucose group (49%), medium group (16%), and high group (35%). The highest prevalence of MACE was seen in the high group (42%) compared to either the medium (39%) or low groups (26%; p<0.001), particularly for cardiogenic shock (p<0.001), cardiac failure (p<0.001) and death (p<0.001). Following multivariable logistic regression analyses of clinical and laboratory parameters associated with mortality, high admission blood glucose conferred a signifi cantly increased odds of mortality (p=0.001). The optimal cut-off admission blood glucose value as determined via the receiver operating characteristic curve for predicting in hospital and 6 months' mortality was 8.5mmol/l (AUC of 0.63) and 8.1mmol/l (AUC of 0.61) for MACE. Conclusions: This study shows that patients have multiple risk factors for AMI with diabetes playing a central role. Although elevated admission blood glucose is an important predictor for in hospital and shortterm MACE, the cut-off value for predicting MACE and mortality has only modest predictability and further research is required to improve the performance of these measures for routine clinical use.

show abstract

Section: Discussionmentioning

confidence: 99%

Admission blood glucose as a prognostic indicator in patients with acute myocardial infarction

Russel¹,

Ranjith²,

Sartorius³

2019

SAHJ

View full text Add to dashboard Cite

show abstract

“…Several metabolic dysregulations occurring in cardiomyocytes as well as in other tissues were associated with a large spectrum of CV diseases. 85 The human metabolome refers to the complete set of small molecules including endogenous metabolites (eg, amino acids, organic acids, nucleic acids, fatty acids, amines, sugars, vitamins, co-factors, pigments, antibiotics, etc) and exogenous chemicals (such as drugs, environmental contaminants, food additives, toxins and other xenobiotics) as products of metabolic reactions on July 7, 2020 by guest. Protected by copyright.…”

Section: Circulating Metabolitesmentioning

confidence: 99%

“…86 All of these metabolites can be measured by using different advanced metabolomics platforms including nuclear magnetic resonance (NMR spectroscopy), mass spectrometry (MS), liquid chromatography (LC), gas chromatography or capillary electrophoresis to facilitate compound separation. 85 Basic findings from metabolomics applications are contributing to better clarifying the metabolic unbalance that occurs in CV diseases suggesting useful non-invasive circulating biomarkers. Moreover, Würtz et al 87 conducted NMR metabolomics to three large cohorts in order to identify circulating biomarkers of incident CV events.…”

Section: Circulating Metabolitesmentioning

confidence: 99%

Fluid-based assays and precision medicine of cardiovascular diseases: the ‘hope’ for Pandora’s box?

2019

View full text Add to dashboard Cite

Progresses in liquid-based assays may provide novel useful non-invasive indicators of cardiovascular (CV) diseases. By analysing circulating cells or their products in blood, saliva and urine samples, we can investigate molecular changes present at specific time points in each patient allowing sequential monitoring of disease evolution. For example, an increased number of circulating endothelial cells may be a diagnostic biomarker for diabetic nephropathy and heart failure with preserved ejection fraction. The assessment of circulating cell-free DNA (cfDNA) levels may be useful to predict severity of acute myocardial infarction, as well as diagnose heart graft rejection. Remarkably, circulating epigenetic biomarkers, including DNA methylation, histone modifications and non-coding RNAs are key pathogenic determinants of CV diseases representing putative useful biomarkers and drug targets. For example, the unmethylated FAM101A gene may specifically trace cfDNA derived from cardiomyocyte death providing a powerful diagnostic biomarker of apoptosis during ischaemia. Moreover, changes in plasma levels of circulating miR-92 may predict acute coronary syndrome onset in patients with diabetes. Now, network medicine provides a framework to analyse a huge amount of big data by describing a CV disease as a result of a chain of molecular perturbations rather than a single defect (reductionism). We outline advantages and challenges of liquid biopsy with respect to traditional tissue biopsy and summarise the main completed and ongoing clinical trials in CV diseases. Furthermore, we discuss the importance of combining fluid-based assays, big data and network medicine to improve precision medicine and personalised therapy in this field.

show abstract

“…Molecular mechanism investigation provides useful information related to diseases that could be used in their management [3]. High throughput methods such as proteomics, genomics, and metabolomics are the advanced method used widely to investigate molecular aspects of many diseases [4][5][6]. In the metabolomics studies, differentially levels of metabolites such as lipids, amino acids, and organic acids in the patient samples rel-GMJ.2020;9:e1696 www.gmj.ir ative to the controls are evaluated [7].…”

Section: Introductionmentioning

confidence: 99%

Introducing Serine as Cardiovascular Disease Biomarker Candidate via Pathway Analysis

Tavirani

Azodi

Rostami‐Nejad

et al. 2020

GMJ

View full text Add to dashboard Cite

Background: The rate of death due to cardiovascular disease (CVD) is growing. Investigations about CVD that leading to introduce varieties of metabolites is available. The monitoring of these metabolites to find effective ones in the future of clinic applications is the main aim of this study. Materials and Methods: Numbers of 34 metabolites for the CVD are extracted from literature and designated for interaction determinations by MetScape V 3.1.3. The compound-reaction-enzyme-gene network was constructed and the pathways were analyzed. Based on the presence of metabolites in the pathways the critical compounds were determined. Results: Pathway analysis revealed 18 disturbed pathways related to the CVD. glycerophospholipid metabolism pathway including 27 compounds is related to the 9 queried metabolites. L-Serine which was communed between 5 pathways and also was presented in the largest pathway was identified as the critical compound. Conclusion: It can be concluded that L-Serine is a proper biomarker candidate for CVD diagnosis and also patients follow up approaches. [GMJ.2020;9:e1696]

show abstract

Cardiovascular Metabolomics

Cited by 329 publications

References 171 publications

Admission blood glucose as a prognostic indicator in patients with acute myocardial infarction

Admission blood glucose as a prognostic indicator in patients with acute myocardial infarction

Fluid-based assays and precision medicine of cardiovascular diseases: the ‘hope’ for Pandora’s box?

Introducing Serine as Cardiovascular Disease Biomarker Candidate via Pathway Analysis

Contact Info

Product

Resources

About